MedTrace Logo

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

NCT03332186 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-09-11

No results posted yet for this study

Summary

The purpose of this study is to investigate experimental medication BMS-986231 in patients with different levels of kidney function.

Conditions

  • Myocardial Failure
  • Cardiac Failure
  • Congestive Heart Failure
  • Kidney Failure
  • Renal Failure

Interventions

DRUG

BMS-986231

Intravenous infusion administration

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2018-10-22
Completion
2018-10-22
FDA Drug
Yes

Countries

  • Czechia
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03332186 on ClinicalTrials.gov